Genfit (NASDAQ:GNFT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genfit (NASDAQ:GNFT) in a report published on Friday,Benzinga reports. The brokerage currently has a $13.00 price target on the stock.

Genfit Price Performance

Genfit stock opened at $3.91 on Friday. The company’s 50-day moving average price is $3.76 and its 200-day moving average price is $4.43. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. Genfit has a twelve month low of $3.35 and a twelve month high of $6.42.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.